ADDF-HARRINGTON SCHOLAR AWARD

OVERVIEW
The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute® have partnered to accelerate the translation of academic discoveries into medicines for treating, preventing, or curing patients with Alzheimer’s disease and related dementias. The ADDF-Harrington Scholar Award provides dedicated support from a project management team and pharmaceutical industry experts, as well as funding of up to $600,000 for 2 years.

Eligibility: MD or PhD researchers in the U.S., Canada and U.K.

AWARD BENEFITS
- Grant Funding
- Drug discovery and pharma expertise
- Business and commercialization advice
- Ability to maximize potential for clinical success

AREAS OF FOCUS
Novel approaches to treat Alzheimer’s disease and related dementias. Of particular interest are targets related to neurovascular health and epigenetics.

TIMELINE
- CALL FOR LETTERS OF INTENT OPENS: June 1, 2022
- LETTERS OF INTENT DEADLINE (EXTENDED): July 25, 2022
- FULL APPLICATION DEADLINE FOR THOSE INVITED: October 24, 2022
- SCHOLARS ANNOUNCED: April 2023

LEARN MORE
harringtondiscovery.org/ADDF

QUESTIONS?
grants@alzdiscovery.org

APPLY
addf.fluxx.io/user_sessions/new

Harrington Discovery Institute
University Hospitals | Cleveland, Ohio

© 2022 University Hospitals
Harrington Discovery Institute® is a registered U.S. trademark of University Hospitals Health System, Inc., and used with permission.

Harrington Discovery Institute’s UK Granting Organization: FUND FOR CURES UK, LTD. Registered Charity